Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Levonorgestrel may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for A Levonorgestrel 1.5mg tablet is an emergency contraceptive that can be used within 72 hours (3 days) of unprotected sex or if your usual contraceptive method has failed. It is about the following cases:
e Levonorgestrel 1.5mg tablets Do not use Levonorgestrel 1.5mg tablets
Warnings and precautions If any of the following applies to you, talk to your doctor before taking Levonorgestrel 1.5mg tablets as emergency contraception may not be suitable for you. Your doctor may prescribe another type of emergency contraception for you.
• •
a medicine used to treat fungal infections (griseofulvin) herbal remedies containing St John's wort (Hypericum perforatum)
Talk to your pharmacist or doctor if you need further advice on the correct dose for you. Consult a doctor as soon as possible after taking the tablets for further advice on a reliable form of regular contraception and to exclude a pregnancy (See also section 3 "How to take Levonorgestrel 1.5mg tablets" for further advice). Levonorgestrel 1.5mg tablets may also affect how well other medicines work
Driving and using machines Your Levonorgestrel 1.5mg tablet is unlikely to affect your ability to drive a car or use machines. However, if you feel tired or dizzy do not drive or operate machinery. 3
Levonorgestrel 1.5mg tablets contain lactose In case of milk sugar (lactose) intolerance it should be considered that each Levonorgestrel 1.5mg tablet also contains 140.1mg lactose monohydrate. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Levonorgestrel 1.5mg tablets Always use this medicine exactly as described in the leaflet or as your pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Use in children and adolescents Levonorgestrel 1.5mg is not indicated for use before the first menstrual bleeding (menarche). Take the tablet as soon as possible, preferably within 12 hours, and no later than 72 hours (3 days) after you have had unprotected sex. Do not delay taking the tablet. The tablet works best the sooner you take it after having unprotected sex. It can only prevent you becoming pregnant, if you take it within 72 hours of unprotected sex. Levonorgestrel 1.5mg tablets can be taken at any time in your menstrual cycle assuming you are not already pregnant or think you may be pregnant. Do not chew but swallow the tablet whole with water.
doctor as soon as possible. If you do become pregnant even after taking this medicine, it is important that you see your doctor. Your doctor can also tell you about longer-term methods of contraception which are more effective in preventing you from getting pregnant. If you continue to use regular hormonal contraception such as the contraceptive pill and you do not have a bleed in your pill-free period, see your doctor to make sure you are not pregnant. Your next period after you took Levonorgestrel 1.5mg tablets After the use of Levonorgestrel 1.5mg tablets, your period is usually normal and will start at the usual day; however sometimes this will be a few days later or earlier. If your period starts more than 5 days later than expected, an 'abnormal' bleeding occurs at that time or if you think that you might be pregnant, you should check whether you are pregnant by a pregnancy test. If you take more Levonorgestrel 1.5mg tablets than you should Although there have been no reports of serious harmful effects from taking too many tablets at once, you may feel sick, actually be sick (vomit), or have vaginal bleeding. You should ask your pharmacist, doctor, practice nurse or family planning clinic for advice, especially if you have been sick, as the tablet may not have worked properly. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Very common (may affect more than 1 in 10 people):
Levonorgestrel 1.5mg tablets Keep this medicine out of the sight and reach of children. 5
Do not use Levonorgestrel 1.5mg tablets after the expiry date which is stated on the package after EXP. The expiry date refers to the last day of the month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment. Store below 25°C. Store in the original package in order to protect from light.
What Levonorgestrel 1.5mg tablets contain The active substance is levonorgestrel. Each tablet contains 1.5mg of levonorgestrel. The other ingredients are: Lactose monohydrate Maize starch Povidone K30 Silica, colloidal anhydrous Magnesium stearate What Levonorgestrel 1.5mg tablets look like and contents of the pack White to off-white round shaped tablets, debossed with "LV1" on one side and plain on the other side. PVC/PVDC/aluminium blister containing one tablet, which is further packed into a carton. Marketing Authorisation Holder and Manufacturer Lupin Healthcare (UK) Ltd. The Urban Building, 2nd floor 3-9 Albert Street, Slough, Berkshire SL1 2BE, United Kingdom This leaflet was last revised in October 2021.
6
Levonorgestrel 1.5mg Tablets comes as tablet containing 1.5mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Levonorgestrel 1.5mg Tablets is levonorgestrel.
Medicines with the same active substance, strength and form include: Emerres 1.5 mg tablet, Emerres Una 1.5 mg tablet, LoviOne 1.5 mg Tablet. In total there are 4 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Levonorgestrel 1.5mg Tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Emergency contraception within 72 hours of unprotected sexual intercourse or failure of a contraceptive method.
.
Posology
One tablet should be taken as soon as possible, preferably within 12 hours, and no later than 72 hours after unprotected intercourse (see section 5.1).
If vomiting occurs within three hours of taking the tablet, another tablet should be taken immediately.
Women who have used enzyme-inducing drugs during the last 4 weeks and need emergency contraception are recommended to use a non-hormonal EC (emergency contraception), i.e. Cu-IUD or take a double dose of levonorgestrel (i.e. 2 tablets taken together) for those women unable or unwilling to use Cu-IUD (see section 4.5).
Levonorgestrel 1.5mg tablets can be used at any time during the menstrual cycle unless menstrual bleeding is overdue.
After using emergency contraception it is recommended to use a local barrier method (e.g. condom, diaphragm, spermicide, cervical cap) until the next menstrual period starts. The use of levonorgestrel does not contraindicate the continuation of regular hormonal contraception.
Paediatric population
There is no relevant use of levonorgestrel for children of prepubertal age in the indication emergency contraception.
Method of administration
For oral administration
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Emergency contraception is an occasional method. It should in no instance replace a regular contraceptive method.
Emergency contraception does not prevent a pregnancy in every instance. If there is uncertainty about the timing of the unprotected intercourse or if the woman has had unprotected intercourse more than 72 hours earlier in the same menstrual cycle, conception may have occurred. Treatment with levonorgestrel following the second act of intercourse may therefore be ineffective in preventing pregnancy. If menstrual periods are delayed by more than 5 days or abnormal bleeding occurs at the expected date of menstrual periods or pregnancy is suspected for any other reason, pregnancy should be excluded.
If pregnancy occurs after treatment with levonorgestrel, the possibility of an ectopic pregnancy should be considered. The absolute risk of ectopic pregnancy is likely to be low, as levonorgestrel prevents ovulation and fertilisation. Ectopic pregnancy may continue, despite the occurrence of uterine bleeding.
Therefore, levonorgestrel is not recommended for patients who are at risk of ectopic pregnancy (previous history of salpingitis or of ectopic pregnancy).
Levonorgestrel is not recommended in patients with severe hepatic dysfunction.
Severe malabsorption syndromes, such as Crohn's disease, might impair the efficacy of levonorgestrel.
This medicinal product contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
After levonorgestrel intake, menstrual periods are usually normal and occur at the expected date. They can sometimes occur earlier or later than expected by a few days. Women should be advised to make a medical appointment to initiate or adopt a method of regular contraception. If no withdrawal bleed occurs in the next pill-free period following the use of levonorgestrel after regular hormonal contraception, pregnancy should be ruled out.
Repeated administration within a menstrual cycle is not advisable because of the possibility of disturbance of the cycle.
Limited and inconclusive data suggest that there may be reduced efficacy of Levonorgestrel 1.5mg tablets with increasing body weight or body mass index (BMI) (see section 5.1 and 5.2). In all women, emergency contraception should be taken as soon as possible after unprotected intercourse, regardless of the woman's body weight or BMI.
Levonorgestrel is not as effective as a conventional regular method of contraception and is suitable only as an emergency measure. Women who present for repeated courses of emergency contraception should be advised to consider long-term methods of contraception.
Use of emergency contraception does not replace the necessary precautions against sexually transmitted diseases.
The metabolism of levonorgestrel is enhanced by concomitant use of liver enzyme inducers, mainly CYP3A4 enzyme inducers. Concomitant administration of efavirenz has been found to reduce plasma levels of levonorgestrel (AUC) by around 50%.
Drugs suspected of having similar capacity to reduce plasma levels of levonorgestrel include barbiturates (including primidone), phenytoin, carbamazepine, herbal medicines containing Hypericum perforatum (St.John's Wort), rifampicin, ritonavir, rifabutin, griseofulvin.
For women who have used enzyme-inducing drugs in the past 4 weeks and need emergency contraception, the use of non-hormonal emergency contraception (i.e. a Cu-IUD) should be considered. Taking a double dose of levonorgestrel (i.e. 3000 mcg within 72 hours after the unprotected intercourse) is an option for women who are unable or unwilling to use a Cu-IUD, although this specific combination (a double dose of levonorgestrel during concomitant use of an enzyme inducer) has not been studied.
Medicines containing levonorgestrel may increase the risk of cyclosporine toxicity due to possible inhibition of cyclosporin metabolism.
Pregnancy
Levonorgestrel should not be given to pregnant women. It will not interrupt a pregnancy. In the case of continued pregnancy, limited epidemiological data indicate no adverse effects on the fetus but there are no clinical data on the potential consequences if doses greater than 1.5 mg of levonorgestrel are taken (see section 5.3.).
Breast-feeding
Levonorgestrel is secreted into breast milk. Potential exposure of an infant to levonorgestrel can be reduced if the breast-feeding woman takes the tablet immediately after feeding and avoids nursing at least 8 hours following levonorgestrel administration.
Fertility
Levonorgestrel increases the possibility of cycle disturbances which can sometimes lead to earlier or later ovulation date resulting in modified fertility date. Although there are no fertility data in the long term, after treatment with levonorgestrel a rapid return to fertility is expected and therefore, regular contraception should be continued or initiated as soon as possible after levonorgestrel EC use.
No studies on the effect on the ability to drive and use machines have been performed.
The most commonly reported undesirable effect was nausea.
All adverse drug reactions are listed by system, organ class and frequency.
System Organ Class
Frequency of adverse reactions
Very common (≥ 1/10)
Common (≥1/100 to <1/10)
Nervous system disorders
Headache
Dizziness
Gastrointestinal disorders
Nausea
Abdominal pain lower
Diarrhoea
Vomiting
Reproductive system and breast disorders
Bleeding not related to menses*
Delay of menses more than 7 days **
Menstruation irregular
Breast tenderness
General disorders and administration site conditions
Fatigue
* Bleeding patterns may be temporarily disturbed, but most women will have their next menstrual period within 5-7 days of the expected time.
** If the next menstrual period is more than 5 days overdue, pregnancy should be excluded.
From Post-marketing surveillance additionally, the following adverse events have been reported:
Gastrointestinal disorders
Very rare (<1/10,000): abdominal pain
Skin and subcutaneous tissue disorders
Very rare (<1/10,000): rash, urticaria, pruritus,
Reproductive system and breast disorders
Very rare (<1/10,000): pelvic pain, dysmenorrhoea
General disorders and administration site conditions
Very rare (<1/10,000): face oedema
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Serious undesirable effects have not been reported following acute ingestion of large doses of oral contraceptives. Overdose may cause nausea, and withdrawal bleeding may occur. There are no specific antidotes and treatment should be symptomatic.
Ask anything about Levonorgestrel 1.5mg Tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.